Status:
COMPLETED
A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
American Cancer Society, Inc.
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The scientific premise for this study is the known impact of overweight/obesity on breast cancer risk and outcomes, the association between advanced glycation end-products (AGE) and high fat, highly p...
Eligibility Criteria
Inclusion
- Diagnosis of breast cancer, any subtype, stage I-III, within the last 36 months, who have completed primary therapy of their breast cancer (surgery, radiation, and chemotherapy). Must be at least 4 weeks post their last chemotherapy or radiation therapy. Concurrent hormonal therapy is allowed.
- At least 18 years of age.
- Determined to have a high AGE diet at baseline (dietary AGE intake greater than 14 Eq/day as assessed by food frequency questionnaire).
- Ability to understand and willingness to sign an IRB approved written informed consent document.
Exclusion
- Diagnosis of diabetes.
- History of eating disorder or body dysmorphic disorder.
- Active tobacco use (tobacco is a source of advanced glycation end products).
- Active participation in other dietary or physical activity clinical trials or community interventions.
- Taking and unwilling/unable to stop taking B-6 (pyridoxamine), B1 (thiamine) or metformin (all known AGE inhibitors).
Key Trial Info
Start Date :
October 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 22 2024
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05265715
Start Date
October 14 2022
End Date
March 22 2024
Last Update
January 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110